Lu M, Kim MJ, Collins EC et al. Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA Neurol. 2025 Oct 13.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2839837
